AstraZeneca Imfinzi approved by FDA for postoperative adjuvant therapy in non-small cell lung cancer patients
海角七号
发表于 2024-8-16 13:21:22
211
0
0
The US Food and Drug Administration (FDA) approved a new therapy for the best-selling anti-cancer drug Imfinzi from British pharmaceutical giant AstraZeneca on Thursday (August 15th).
According to media reports on Friday, the FDA has approved Imfinzi as an additional treatment for adult non-small cell lung cancer (NSCLC) patients after surgery.
About one-fifth of all cancer deaths are attributed to lung cancer. Lung cancer is roughly divided into non-small cell lung cancer and small cell lung cancer (SCLC), with approximately 15% of cases classified as small cell lung cancer and the remaining 85% as non-small cell lung cancer.
Imfinzi, as a human monoclonal antibody, helps activate existing anti-cancer immune cells in patients' bodies, more accurately blocking the ability of tumors to evade and suppress the immune system, while enhancing the body's anti-cancer immune response, providing an alternative to chemotherapy.
The data also shows that the drug improved the overall survival rate of a type of lung cancer patient.
The drug was officially approved in the United States in 2017 for the treatment of locally advanced non-small cell lung cancer patients who cannot undergo surgical resection. The cancer cells of these patients are usually unable to be surgically removed, and the disease does not progress after platinum based radiotherapy and chemotherapy, making Imfinzi an alternative immunotherapy.
Earlier this Thursday, AstraZeneca released a press release stating that it has received FDA's priority review for the use of Imfinzi in small cell lung cancer patients with a limited time limit. The FDA's regulatory decision is expected to be officially implemented in the fourth quarter of 2024.
This news pushed the company's stock price to a historic high of £ 132.18 ($170.13) per share during the day, closing at £ 131.66 per share.
Earlier this month, AstraZeneca's market value exceeded £ 200 billion for the first time, firmly ranking as the highest valued listed company in the UK. In US dollar terms, AstraZeneca's market value ranks seventh in Europe.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Li Xiande from Jingke Energy: Maintain strategic patience during the industry's lowest period of downturn. Unprofitable production capacity will be quickly phased out
- Federal Reserve Governor Waller: Stay patient with interest rate cuts, wait for more data!
- Pfizer Besponsa has been approved by the FDA for the treatment of pediatric patients
- The latest research: Wegovy is also effective for patients with diabetes and heart failure
- BeiGene Terezumab has been approved by the European Commission for the treatment of non-small cell lung cancer
- Zaiding Pharmaceutical: Ruiputinib has been approved by the state for the treatment of ROS1 positive non-small cell lung cancer patients
- Anjin small cell lung cancer treatment drug approved by FDA: can reduce tumor size and prolong lifespan
- AstraZeneca: Targeted lung cancer drug Teresa? Indications for first-line combined chemotherapy for advanced non-small cell lung cancer with EGFR mutation approved in China
- American brain computer company pioneers: Empowering patients with communication skills through OpenAI models
- Baidu Health Platform has attracted over 300000 doctors to join and serve over 210 million patients
-
隔夜株式市場 世界の主要指数は金曜日に多くが下落し、最新のインフレデータが減速の兆しを示したおかげで、米株3大指数は大幅に回復し、いずれも1%超上昇した。 金曜日に発表されたデータによると、米国の11月のPC ...
- SNT
- 前天 12:48
- 支持
- 反对
- 回复
- 收藏
-
長年にわたって、昔の消金大手の捷信消金の再編がようやく地に着いた。 天津銀行の発表によると、同行は京東傘下の2社、対外貿易信託などと捷信消金再編に参加する。再編が完了すると、京東の持ち株比率は65%に達し ...
- SNT
- 前天 12:09
- 支持
- 反对
- 回复
- 收藏
-
【GPT-5屋台で大きな問題:数億ドルを燃やした後、OpenAIは牛が吹くのが早いことを発見した】OpenAIのGPT-5プロジェクト(Orion)はすでに18カ月を超える準備をしており、関係者によると、このプロジェクトは現在進 ...
- SNT
- 8 小时前
- 支持
- 反对
- 回复
- 收藏
-
【英偉達はExBody 2システムを発売して2足ロボットのバランスと適応能力を強化】12月18日、英偉達、MIT、カリフォルニア大学は共同で最新の研究を発表し、ロボットが「固定シナリオ」による運動限界を打破し、ロボ ...
- smile929
- 2 小时前
- 支持
- 反对
- 回复
- 收藏